Richard Phoon

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

<scp>KHA‐CARI</scp> Guideline: Early chronic kidney disease: Detection, prevention and management

David W. Johnson, Emelia Atai, Maria Chan et al. · Nephrology · 2013 · 180 citations · Full text

Medicine, Chronic Disease Prevention, Nephrology +16

IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen

Joshua D. Ooi, Richard Phoon, Stephen R. Holdsworth et al. · Journal of the American Society of Nephrology · 2009 · 120 citations · Full text

Life Sciences, Immunology, Nephrology +16

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

Richard Lafayette, Sean Barbour, Rubeen Israni et al. · Kidney International · 2024 · 117 citations · Full text

Medicine, Nephrology, Pharmacotherapy +16

Knowledge deficit of patients with stage 1–4 <scp>CKD</scp>: A focus group study

Pamela Lopez‐Vargas, Allison Tong, Richard Phoon et al. · Nephrology · 2014 · 96 citations

Nursing, Health Behavior, Nephrology +17